PMC:7594251 / 62284-62450
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T454 | 61-62 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T77748 | 4-8 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T85611 | 117-124 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
| T16775 | 126-130 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T429 | 0-166 | Sentence | denotes | The drug design approach based on diffusion NMR is basically a screening technique used to differentiate the binding ligands (drug) from non-binding components [264]. |